Vancouver, BC, May 29, 2007--(T-Net)--QLT (NASDAQ: QLTI; TSX: QLT) announced today that QLT USA, Inc. submitted a labeling supplement (sNDA) for Aczone to the U.S. Food and Drug Administration to request the removal of the gluceose-6-phosphate dehydrogenase screening and blood monitoring requirements from its current label.
From: www.bctechnology.com
QLT USA Files Aczone Labeling Supplement for Removal of Blood Screening Requirement
Posted by Ruslan Abuzant at 9:32 AM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment